Burow Kristina's Form 4 filing
Neumora Therapeutics, Inc. (NMRA) · filed Sep 20, 2023
- Accession no.
- 0001610717-23-000291
- Filed
- Sep 20, 2023
- Trade date
- Sep 19, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 7 non-derivative transactions and 6 derivative transactions. Open-market purchases total $25.5M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Burow KristinaCIK 0001569248 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 19, 2023 | Common Stock | CConversionAcquired | +13,620 | –F1 | – | 13,620 | Direct | |
| Sep 19, 2023 | Common Stock | CConversionAcquired | +684,167 | –F1 | – | 684,167 | Indirect | |
| Sep 19, 2023 | Common Stock | CConversionAcquired | +1,144,973 | –F1 | – | 1,144,973 | Indirect | |
| Sep 19, 2023 | Common Stock | CConversionAcquired | +6,895,021 | –F1 | – | 12,205,379 | Indirect | |
| Sep 19, 2023 | Common Stock | CConversionAcquired | +6,576,400 | –F1 | – | 11,886,758 | Indirect | |
| Sep 19, 2023 | Common Stock | CConversionAcquired | +2,124,143 | –F1 | – | 2,124,143 | Indirect | |
| Sep 19, 2023 | Common Stock | PPurchaseAcquired | +1,500,000 | $17.00 | +$25,500,000 | 3,624,143 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 19, 2023 | Common Stock | CConversionDisposed | −13,620 | –F1 | – | 0 | Direct | |
| Sep 19, 2023 | Common Stock | CConversionDisposed | −684,167 | –F1 | – | 0 | Indirect | |
| Sep 19, 2023 | Common Stock | CConversionDisposed | −1,144,973 | –F1 | – | 0 | Indirect | |
| Sep 19, 2023 | Common Stock | CConversionDisposed | −6,895,021 | –F1 | – | 0 | Indirect | |
| Sep 19, 2023 | Common Stock | CConversionDisposed | −6,576,400 | –F1 | – | 0 | Indirect | |
| Sep 19, 2023 | Common Stock | CConversionDisposed | −2,124,143 | –F1 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.
Referenced by the price of 6 transactions in Table I and 6 transactions in Table II.